&P UPGRADES RECOMMENDATION ON SHARES OF MEDAREX TO BUY FROM HOLD Thursday 02/26/2009 10:14 AM ET - Standard & Poor's Research Notes Q4 adjusted loss of $0.28 vs. loss of $0.35 is $0.09 narrower than our loss estimate. We see solid pipeline progress and believe MEDX remains among the best capitalized small biotech companies, with $354M in cash and $87M in equity interests as of December 31, 2008. We are encouraged by recent approvals in E.U. and Canada of Stelara, the first human antibody generated by MEDX's UltiMAb technology to gain market approval. We expect U.S. approval this year. We also see MDX-066 and MDX-1388 progressing to Phase III trials and potential partnerships. We keep our target price of $10.
Market Data 
Markets 
AI
